Healthcare
Live Price
Offline$38.33
-2.55% today
1Y Change
+40.60%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Gedeon Richter PLC (RGEDF) is a Healthcare stock with a market cap of $2.39T and listed on OTC. The stock last traded around $38.33 and up 40.6% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of +8.3%, EPS growth of -2.8%, a dividend yield of 3.9%. What stands out right now is revenue +8.3%, EPS -2.8%, free cash flow +2.3% with operating margin 33.2% and ROIC 16.6%. The dividend matters to the case here, with a current yield around 3.9%. Valuation is more restrained than many high-expectation growth names at P/E 10.3 and price/sales 2.6. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines RGEDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGEDF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RGEDF Max Drawdown
-15.63%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RGEDF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$630.6B
-21.4% YoY
FY Net Income
$139.6B
-17.4% YoY
Free Cash Flow
$93.8B
-26.0% YoY
Revenue Growth
+8.3%
EPS Growth
-2.8%
Gross Margin
68.1%
Net Margin
25.0%
Income statement
HUF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 929.0B | 857.5B | 805.2B | 802.8B | 630.6B |
| Gross Profit | 640.9B | 590.7B | 521.3B | 460.5B | 349.3B |
| Operating Income | 323.7B | 256.2B | 189.4B | 168.5B | 139.8B |
| EBITDA | 323.7B | 335.5B | 262.6B | 233.6B | 175.6B |
| Net Income | 232.3B | 239.2B | 158.8B | 169.1B | 139.6B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
HUF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 211.8B | 135.6B | 80.5B | 79.7B | 59.9B |
| Total Assets | 1681.3B | 1603.0B | 1361.2B | 1353.8B | 1145.3B |
| Total Liabilities | 280.4B | 299.1B | 218.6B | 279.9B | 222.3B |
| Shareholder Equity | 1398.4B | 1300.5B | 1130.8B | 1063.4B | 914.9B |
| Total Debt | 35.3B | 99.7B | 87.0B | 85.1B | 84.3B |
| Net Debt | -176.5B | -113.9B | 6.5B | 5.4B | 24.4B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
139.9B
-24.8% YoY
Capital Expenditures
46.1B
+22.1% YoY
Free Cash Flow
93.8B
-26.0% YoY
Key ratios
Gross Margin
68.1%
Operating Margin
33.2%
Net Margin
25.0%
ROE
17.3%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.